Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Ophthalmology · Thyroid Eye Disease

Who Is Most at Risk for Severe Thyroid Eye Disease?

At a Glance

Older men, especially those over 50, have a higher statistical risk of severe thyroid eye disease, particularly muscle-related problems and optic nerve compression. Smoking, unstable thyroid levels, and diabetes can add risk, so monitoring and urgent evaluation of vision changes are important.

While Thyroid Eye Disease (TED) is diagnosed more frequently in women, population studies show that, on average, older men have a higher risk of developing severe complications [1]. If you are a man over 50 who has recently been diagnosed with TED, research indicates that your age and sex are statistically associated with a higher likelihood of significant eye muscle involvement [2][3].

However, it is vital to remember that risk is not destiny. These demographic trends do not guarantee you will develop severe disease. Many people in this demographic are managed successfully without sight-threatening complications. Your individual risk is shaped much more by your specific examination findings, disease activity, and modifiable factors like smoking and thyroid control.

How Age and Sex Influence TED Patterns

TED affects different people in different ways, and the patterns often overlap. In many younger patients, the condition tends to cause the fatty tissue behind the eye to expand, leading to mild or moderate bulging (exophthalmos) [4].

While any patient can develop any form of TED, older men are more likely to develop muscle-predominant TED [5]. In TED, the autoimmune system targets cells called orbital fibroblasts. This triggers inflammation and swelling in the tissues around and within the extraocular muscles (the small muscles that move your eyes) [6]. For older men, this inflammation often leads to markedly enlarged and stiff eye muscles.

The Challenges of Muscle-Predominant TED

When the eye muscles become significantly enlarged and stiffened, the risk increases for two major complications:

  • Severe Double Vision (Diplopia): As the eye muscles become stiff—a condition called restrictive myopathy—they cannot move the eyes together smoothly. This can result in persistent double vision and strabismus (misalignment of the eyes) [7][3].
  • Dysthyroid Optic Neuropathy (DON): DON is a rare but sight-threatening complication. It occurs when enlarged orbital tissues crowd the tight bony space behind the eye (the orbital apex) and compress the optic nerve [8][9]. Research shows that increasing age, particularly over 50 to 55, is a significant statistical risk factor for developing DON [2][10].

⚠️ URGENT WARNING: Optic Nerve Compression
Dysthyroid Optic Neuropathy (DON) can develop subtly and does not require dramatic eye bulging to occur. If you experience a new or worsening decrease in vision sharpness, colors looking washed out or less saturated, unexplained dimming or graying of your vision, or missing spots in your field of vision, you must seek urgent, same-day evaluation by an eye care specialist or go to an emergency room [11].

Modifiable Risk Factors You Can Control

While you cannot change your age or sex, several powerful risk factors are within your control. Managing these can help support a safer care path:

  • Smoking: Smoking is one of the most important modifiable risk factors for severe TED and optic neuropathy [10][12]. Quitting smoking and avoiding secondhand smoke significantly reduces your risk of complications. If you smoke, ask your doctor about cessation programs and nicotine-replacement therapy.
  • Thyroid Control: Unstable thyroid levels—both hyperthyroidism (overactive) and hypothyroidism (underactive)—can worsen TED [10]. High levels of thyroid-stimulating antibodies (TRAb) are also a risk marker for severe disease [2]. The goal is to keep your thyroid hormone levels stable through medical guidance. Do not alter your thyroid medication without speaking to your doctor.
  • Diabetes: Epidemiologic studies show an association between diabetes (both type 1 and type 2) and a higher likelihood of sight-threatening complications, including DON [12][13]. While diabetes alone doesn’t directly cause severe double vision, managing your blood sugar supports your overall eye health.

What Happens Next: Monitoring Your Eye Health

Because you fall into a higher-risk demographic, you will likely need baseline and regular evaluations with a specialized eye doctor, such as an oculoplastic surgeon or neuro-ophthalmologist. These specialists are trained in the complex anatomy of the eye socket and optic nerve.

They will not just scan your eye muscles; a proper evaluation for DON involves clinical tests of your visual acuity, color vision, pupil responses, and visual fields [14]. The frequency of your visits will be individualized based on how active your disease is, your specific visual findings, and your treatment plan—not just your age.

Common questions in this guide

Who is more likely to develop severe thyroid eye disease?
Older men, particularly those over 50, have a higher statistical risk of muscle-predominant thyroid eye disease and serious complications than many other groups. Smoking, unstable thyroid hormone levels, high thyroid-stimulating antibodies, and diabetes can increase risk further. These are associations, not a prediction of what will happen to one person.
Does being an older man mean I will develop sight-threatening thyroid eye disease?
No. Age and sex are statistical risk factors, but many older men are managed without sight-threatening complications. Your individual risk depends more on current disease activity, examination findings, thyroid control, smoking, and other health factors.
What vision changes can signal optic nerve compression from thyroid eye disease?
New or worsening loss of vision sharpness, colors that look faded, unexplained dimming or graying, or missing spots in the visual field can be warning signs. Dysthyroid optic neuropathy can develop without dramatic eye bulging. Seek same-day evaluation by an eye specialist or go to an emergency room.
Can smoking make thyroid eye disease more severe?
Yes. Smoking is one of the most important modifiable risk factors for severe thyroid eye disease and optic neuropathy, and secondhand smoke may also matter. Quitting and avoiding secondhand smoke can reduce complication risk; ask your clinician about cessation support and nicotine replacement.
How do thyroid levels and antibodies affect my risk?
Unstable thyroid hormone levels, whether too high or too low, can worsen thyroid eye disease, and high thyroid-stimulating antibody (TRAb) levels are associated with more severe disease. Keep thyroid treatment stable with medical guidance and do not change medication on your own. Ask your clinician how your current results affect your monitoring plan.
What tests monitor for severe thyroid eye disease?
An eye specialist may establish baseline and repeat visual acuity, color vision, pupil responses, and visual-field tests. They may also assess eye movement, muscle involvement, and other findings. Visit frequency depends on disease activity, vision findings, and treatment plan rather than age alone.
Is double vision the same as optic nerve compression?
No. Enlarged, stiff eye muscles can cause restricted eye movement, double vision, and eye misalignment, while dysthyroid optic neuropathy involves pressure on the optic nerve. Double vision still needs evaluation, especially if it is persistent or worsening, but it is not by itself proof of optic nerve damage.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on thyrotoxic exophthalmos.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my current examination, how often should we be testing my visual acuity, color vision, and visual fields to monitor for optic nerve compression?
  2. 2.How do my current thyroid antibody (TRAb) levels and overall thyroid stability affect my individual risk?
  3. 3.What baseline measurements will be recorded today to track my disease progress over time?
  4. 4.If my double vision becomes significant, what are my temporary options, such as prisms or occlusion, so I can maintain my daily activities safely?

References

References (14)
  1. 1

    Call for timely prevention in thyroid eye disease: lessons from the IrTED registry.

    Karimi N, Akbarian S, Ghahvehchian H, et al.

    The British journal of ophthalmology 2026; (110(3)):256-261 doi:10.1136/bjo-2025-327392.

    PMID: 40940144
  2. 2

    Predictive demographic and clinical features for the development of dysthyroid optic neuropathy in a multi-ethnic TED population: a retrospective cohort study.

    Moledina M, Lee V, Alnahrawy A, et al.

    Thyroid research 2025; (18(1)):37 doi:10.1186/s13044-025-00249-4.

    PMID: 40691639
  3. 3

    Low clinical activity score, 'progressive' thyroid eye disease: presentations of 1439 patients from a tertiary centre in Hong Kong.

    Lai KKH, Aljufairi FMAA, Sebastian JU, et al.

    The British journal of ophthalmology 2025; (109(6)):715-720 doi:10.1136/bjo-2024-325346.

    PMID: 39798945
  4. 4

    Quantification of optic nerve length and tortuosity in thyroid eye disease.

    Ugradar S, Rootman DB

    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2019; (54(5)):611-614 doi:10.1016/j.jcjo.2019.01.007.

    PMID: 31564353
  5. 5

    Correlation between extraocular muscle enlargement and thyroid autoantibodies in thyroid eye disease.

    Koizumi T, Tanaka T, Umeda K, et al.

    Japanese journal of ophthalmology 2024; (68(3)):250-258 doi:10.1007/s10384-024-01061-7.

    PMID: 38609717
  6. 6

    Age differences in clinical manifestation and prognosis of thyroid eye disease.

    Ben Simon GJ, Katz G, Zloto O, et al.

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2015; (253(12)):2301-8 doi:10.1007/s00417-015-3156-2.

    PMID: 26344731
  7. 7

    Clinical characteristics of thyroid eye disease with restrictive strabismus.

    Zhang H, He W

    European journal of ophthalmology 2026; 11206721261461917 doi:10.1177/11206721261461917.

    PMID: 42345442
  8. 8

    Radiological Activity Score (RAS)-MRI Characteristics in Dysthyroid Optic Neuropathy in a Multi-Ethnic Thyroid Eye Disease Population.

    Moledina M, Lee V, Bhatia K, et al.

    Clinical endocrinology 2025; (103(3)):385-395 doi:10.1111/cen.15272.

    PMID: 40391843
  9. 9

    Diagnostic value of MRI and diffusion-weighted imaging in dysthyroid optic neuropathy: a cross-sectional study providing insights into predictive parameters and pathogenesis.

    Potvin ARGG, de Win MML, Bisschop PH, et al.

    Neuroradiology 2025; (67(9)):2563-2572 doi:10.1007/s00234-025-03695-x.

    PMID: 40960511
  10. 10

    Predictive factors of development of dysthyroid optic neuropathy among individuals with thyroid-eye disease.

    Kemchoknatee P, Thongsawangchai N, Srisombut T, et al.

    European journal of ophthalmology 2024; (34(3)):834-842 doi:10.1177/11206721231199868.

    PMID: 37661652
  11. 11

    A Korean Clinical Practice Framework for Thyroid Eye Disease: Integrating International Recommendations with Survey-Informed Consensus.

    Ko J, Surl D, Lee MJ, et al.

    Endocrinology and metabolism (Seoul, Korea) 2026; (41(3)):367-382 doi:10.3803/EnM.2026.2920.

    PMID: 42281219
  12. 12

    Sight-Threatening Thyroid Eye Disease: Role of Diabetes Mellitus and Interaction with Other Risk Factors.

    Rath S, Pattnaik M, Tripathy D, et al.

    Ophthalmic plastic and reconstructive surgery 2021; (37(4)):352-360 doi:10.1097/IOP.0000000000001871.

    PMID: 33060509
  13. 13

    Characteristics of Diabetic and Nondiabetic Patients With Thyroid Eye Disease in the United States: A Claims-Based Analysis.

    Patel VK, Padnick-Silver L, D'Souza S, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2022; (28(2)):159-164 doi:10.1016/j.eprac.2021.11.080.

    PMID: 34781042
  14. 14

    Updates on Treatment in Thyroid Eye Disease for the Neurologist.

    Alryalat SA, Alasheh A, Salim QA, Yaaqba N

    Neurologic clinics 2026; (44(2)):321-335 doi:10.1016/j.ncl.2025.12.002.

    PMID: 41922040

This page is for informational purposes only and does not constitute medical advice. Your eye specialist and thyroid clinician can assess your individual risk; seek same-day care for new or worsening vision changes.